Latest Insider Transactions at Prevail Therapeutics Inc. (PRVL)
This section provides a real-time view of insider transactions for Prevail Therapeutics Inc. (PRVL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Prevail Therapeutics Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Prevail Therapeutics Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 22
2021
|
Peter A. Thompson Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
13,822,463
-100.0%
|
-
|
|
Jan 22
2021
|
Carl L Gordon Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
13,822,463
-100.0%
|
-
|
|
Jan 22
2021
|
Ran Nussbaum Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
1,576,881
-100.0%
|
-
|
|
Jan 22
2021
|
Francois Nader Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
23,747
-100.0%
|
-
|
|
Jan 22
2021
|
Emily Minkow Chief Business Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
13,000
-100.0%
|
-
|
|
Jan 22
2021
|
Asa Abeliovich President & CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
2,385,756
-100.0%
|
-
|
|
Jan 22
2021
|
Orbimed Advisors LLC Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
13,822,463
-100.0%
|
-
|
|
Jan 22
2021
|
Tyto Acquisition Corp > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
34,284,789
+100.0%
|
$754,265,358
$22.5 P/Share
|
|
Dec 30
2020
|
Asa Abeliovich President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
89,037
-3.6%
|
$2,047,851
$23.02 P/Share
|
|
Dec 30
2020
|
Asa Abeliovich President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
125,793
+2.43%
|
$628,965
$5.22 P/Share
|
|
Jun 24
2019
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
882,352
+6.0%
|
$14,999,984
$17.0 P/Share
|
|
Jun 24
2019
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
10,510,111
+44.82%
|
-
|